Canada’s federal health regulator has approved Jazz Pharmaceuticals Canada’s cannabinoid-based medicine Epidiolex as an adjunctive therapy for certain rare and severe forms of epilepsy, allowing the company to bring to market a clinically tested drug with global sales that dwarf those of the nation’s entire medical cannabis industry.
Epidiolex is the top-selling clinically proven cannabinoid-based medicine in the world, with global sales through the first nine months of Jazz’s fiscal year totaling approximately $604.8 million (823 million Canadian dollars).
By comparison, in calendar year 2022, Canadian patients purchased CA$410 million dollars of cannabis products for medical use, 7.4% lower than in 2021, according to Statistics Canada.
Read more
https://mjbizdaily.com/cannabinoid-based-medicine-epidiolex-approved-for-sale-in-canada/